Sientra Inc (SIEN) to Post Q1 2019 Earnings of ($0.81) Per Share, Dougherty & Co Forecasts

Share on StockTwits

Sientra Inc (NASDAQ:SIEN) – Investment analysts at Dougherty & Co issued their Q1 2019 earnings per share estimates for Sientra in a report issued on Wednesday, March 13th. Dougherty & Co analyst K. Bauser anticipates that the medical instruments supplier will post earnings of ($0.81) per share for the quarter. Dougherty & Co currently has a “Buy” rating and a $27.00 price target on the stock. Dougherty & Co also issued estimates for Sientra’s FY2019 earnings at ($2.98) EPS and FY2020 earnings at ($2.32) EPS.

Other research analysts also recently issued research reports about the stock. Maxim Group reissued a “buy” rating and set a $20.00 target price on shares of Sientra in a research report on Monday, February 11th. ValuEngine downgraded shares of Sientra from a “strong-buy” rating to a “buy” rating in a research report on Thursday, January 24th. William Blair downgraded shares of Sientra from an “outperform” rating to a “market perform” rating in a research report on Wednesday. Leerink Swann cut their price objective on shares of Sientra from $22.00 to $18.00 in a research report on Wednesday. Finally, BidaskClub downgraded shares of Sientra from a “sell” rating to a “strong sell” rating in a research report on Tuesday, December 18th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $20.44.

SIEN stock opened at $8.84 on Friday. The company has a current ratio of 2.77, a quick ratio of 2.34 and a debt-to-equity ratio of 0.36. The stock has a market capitalization of $325.46 million, a P/E ratio of -2.72 and a beta of -0.04. Sientra has a 12 month low of $7.74 and a 12 month high of $26.79.

Sientra (NASDAQ:SIEN) last posted its quarterly earnings results on Tuesday, March 12th. The medical instruments supplier reported ($0.86) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.19). The company had revenue of $19.02 million during the quarter, compared to analysts’ expectations of $18.87 million. Sientra had a negative return on equity of 123.50% and a negative net margin of 121.28%.

Several institutional investors have recently modified their holdings of the company. BlackRock Inc. grew its position in shares of Sientra by 2.8% in the 4th quarter. BlackRock Inc. now owns 1,616,583 shares of the medical instruments supplier’s stock worth $20,546,000 after buying an additional 43,684 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Sientra by 1.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,017,312 shares of the medical instruments supplier’s stock worth $24,293,000 after buying an additional 14,422 shares during the last quarter. Vanguard Group Inc grew its position in shares of Sientra by 1.4% in the 3rd quarter. Vanguard Group Inc now owns 1,017,312 shares of the medical instruments supplier’s stock worth $24,293,000 after buying an additional 14,422 shares during the last quarter. Millennium Management LLC grew its position in shares of Sientra by 117.6% in the 4th quarter. Millennium Management LLC now owns 966,106 shares of the medical instruments supplier’s stock worth $12,279,000 after buying an additional 522,153 shares during the last quarter. Finally, Northern Trust Corp grew its position in shares of Sientra by 74.2% in the 2nd quarter. Northern Trust Corp now owns 270,559 shares of the medical instruments supplier’s stock worth $5,278,000 after buying an additional 115,283 shares during the last quarter. 92.79% of the stock is currently owned by hedge funds and other institutional investors.

About Sientra

Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.

Further Reading: Trading Ex-Dividend

Earnings History and Estimates for Sientra (NASDAQ:SIEN)

Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Canadian Imperial Bank of Commerce  Price Target Raised to C$121.00 at Canaccord Genuity
Canadian Imperial Bank of Commerce Price Target Raised to C$121.00 at Canaccord Genuity
Bank of Nova Scotia  PT Lowered to C$74.00
Bank of Nova Scotia PT Lowered to C$74.00
Realty Income  versus MTGE Investment  Critical Contrast
Realty Income versus MTGE Investment Critical Contrast
StorageVault Canada Inc  Forecasted to Post Q1 2020 Earnings of $0.03 Per Share
StorageVault Canada Inc Forecasted to Post Q1 2020 Earnings of $0.03 Per Share
Quaker Chemical  Raised to Hold at Zacks Investment Research
Quaker Chemical Raised to Hold at Zacks Investment Research
Axel Springer  PT Set at €60.00 by JPMorgan Chase & Co.
Axel Springer PT Set at €60.00 by JPMorgan Chase & Co.


 
© 2006-2019 Zolmax.